LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Mameli, Maria Sabrina"
  2. AU="Yong-ming GAO"
  3. AU="Paquette, Kimberly"
  4. AU="Sharawat, Indar Kumar"
  5. AU="Alexandre Alanio"
  6. AU="Caron, Jeffrey G"
  7. AU="Lubisi, Baratang A"
  8. AU="Edelman, Robert R."
  9. AU="van der Werf, Steffie"
  10. AU="Sam, Andrew"

Search results

Result 1 - 2 of total 2

Search options

  1. Article: HIV Infection Indicator Disease-Based Active Case Finding in a University Hospital: Results from the SHOT Project.

    De Vito, Andrea / Colpani, Agnese / Mameli, Maria Sabrina / Bagella, Paola / Fiore, Vito / Fozza, Claudio / Montesu, Maria Antonia / Fois, Alessandro Giuseppe / Filigheddu, Fabiana / Manzoni, Noemi / Putzu, Carlo / Babudieri, Sergio / Madeddu, Giordano

    Infectious disease reports

    2023  Volume 15, Issue 1, Page(s) 94–101

    Abstract: In 2014, UNAIDS launched renewed global targets for HIV control to achieve by 2025, known as "the three 95": 95% of people living with HIV (PWH) diagnosed, of which 95% are receiving treatment, of which 95% are on sustained virological suppression. In ... ...

    Abstract In 2014, UNAIDS launched renewed global targets for HIV control to achieve by 2025, known as "the three 95": 95% of people living with HIV (PWH) diagnosed, of which 95% are receiving treatment, of which 95% are on sustained virological suppression. In Italy, new HIV diagnoses have been steadily decreasing since 2012. However, in 2020, 41% of new diagnoses presented with less than 200 CD4+ cells/µL and 60% with less than 350 CD4+ cells/µL. Implementing testing and early treatment is a key strategy to prevent AIDS, late presentation, and HIV transmission. We selected non-Infectious Diseases Units based on the European project HIDES and engaged colleagues in a condition-guided HIV screening strategy. We enrolled 300 patients, of which 202 were males (67.3%) and 98 were females (32.7%). Most of the screening was performed in Infectious Diseases (ID) and Hematologic wards. In total, we diagnosed eleven new HIV infections with a hospital prevalence in the study population of 3.7%. Five (45.4%) had a CD4 count <100/mm
    Language English
    Publishing date 2023-01-29
    Publishing country Switzerland
    Document type Journal Article
    ISSN 2036-7430
    ISSN 2036-7430
    DOI 10.3390/idr15010010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile.

    Squillace, Nicola / Ricci, Elena / Menzaghi, Barbara / De Socio, Giuseppe Vittorio / Passerini, Simone / Martinelli, Canio / Mameli, Maria Sabrina / Maggi, Paolo / Falasca, Katia / Cordier, Laura / Celesia, Benedetto Maurizio / Salomoni, Elena / Di Biagio, Antonio / Pellicanò, Giovanni Francesco / Bonfanti, Paolo

    Drug design, development and therapy

    2020  Volume 14, Page(s) 5515–5520

    Abstract: Objective: We aimed to investigate the effect of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on the hepatic safety and metabolic profile.: Methods: Consecutive HIV patients, enrolled in the Surveillance Cohort ... ...

    Abstract Objective: We aimed to investigate the effect of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on the hepatic safety and metabolic profile.
    Methods: Consecutive HIV patients, enrolled in the Surveillance Cohort Long-term Toxicity Antiretrovirals/Antivirals (SCOLTA) project, switching from TDF to TAF were included. Changes from baseline (T0) to 6-month follow-up (T1) were evaluated using paired
    Results: A total of 190 patients switched from TDF to TAF and had one 6-month follow-up visit. They were 80% male, 74.2% at CDC stage A-B, 93.7% with undetectable HIV-viral load. Mean age was 46.7±10.7 years, body mass index was 25.0±3.9 kg/m
    Conclusion: A significant reduction of liver enzymes was observed after switching from TDF to TAF, especially in subjects with initial level of ALT >40 IU/L. Glucose, TC, HDL-C, and LDL-C increased, with no effect on cardiovascular risk scores.
    MeSH term(s) Adult ; Aged ; Alanine/pharmacology ; Alanine Transaminase/antagonists & inhibitors ; Alanine Transaminase/metabolism ; Aspartate Aminotransferases/antagonists & inhibitors ; Aspartate Aminotransferases/metabolism ; Enzyme Inhibitors/pharmacology ; Female ; Glucose/analysis ; Humans ; Lipids/analysis ; Male ; Middle Aged ; Tenofovir/analogs & derivatives ; Tenofovir/pharmacology
    Chemical Substances Enzyme Inhibitors ; Lipids ; Tenofovir (99YXE507IL) ; Aspartate Aminotransferases (EC 2.6.1.1) ; Alanine Transaminase (EC 2.6.1.2) ; tenofovir alafenamide (EL9943AG5J) ; Glucose (IY9XDZ35W2) ; Alanine (OF5P57N2ZX)
    Language English
    Publishing date 2020-12-15
    Publishing country New Zealand
    Document type Clinical Trial ; Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 2451346-5
    ISSN 1177-8881 ; 1177-8881
    ISSN (online) 1177-8881
    ISSN 1177-8881
    DOI 10.2147/DDDT.S274307
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top